Wipro Consumer Care Buys 60% Of Skincare Brand DermaTouch

Wipro Consumer Care & Lighting has acquired a 60% stake in skincare brand DERMATOUCH at an enterprise value of Rs 387.5 crore, its entry into India's premium skincare market.

Stake: 60% now, the remaining 40% over the next three years
Enterprise value: Rs 387.5 crore
DermaTouch FY26 revenue: Rs 131 crore, up 114% over FY25
Founders Anish Nagpal and Amit Purswani stay on to run the business with the current management team
Wipro Consumer Care's 18th acquisition globally, and its third in the past month
Existing skincare brands in the group: Derma Lab, Dr. Dermis, Bio-essence

The Multiple Is The Story

Rs 387.5 crore enterprise value against Rs 131 crore of FY26 revenue is roughly three times sales. For a profitable consumer brand growing at 114% a year, that is not an outlandish price, and it is a long way below what Indian D2C beauty was fetching at the peak of the funding cycle.

The structure is the sensible part. Sixty per cent now, forty over three years, founders retained and running it. That keeps the people who built the growth accountable for continuing it, and defers a chunk of the price until they have.

Wipro Consumer Care's First Digital-First Brand

Kumar Chander, CEO of Wipro Consumer Care & Lighting, named the condition the company applied:

"Dermatouch represents an exciting opportunity for us as our first foray into digital brands. We have been clear that we would only look at Digital brands that have the potential to expand offline, which Dermatouch has already proven."

That last clause is the whole thesis. Plenty of Indian D2C brands scale on a marketplace and then stall the moment they meet a distributor, because online performance marketing and offline shelf economics reward completely different things. Wipro is buying a brand that has already crossed that line, rather than betting it can.

The Marketing Question It Raises

Three acquisitions in a month, eighteen globally, and now a portfolio holding four skincare brands including Derma Lab, Dr. Dermis and Bio-essence. The obvious question is how those are positioned against each other once they share a distribution network and a media budget.

Founders Nagpal and Purswani described Wipro's distribution reach and research capability as what makes it the right partner. That is the standard case, and it is genuinely the strongest argument for selling to an FMCG group rather than raising again. The risk running the other way is the familiar one: a science-led brand that grew on sharp, narrow claims can lose the thing that made it work once it has to speak to a mass shelf.